What is Stella?
Stella operates at the intersection of advanced anesthesiology and mental health, primarily focusing on the Stellate Ganglion Block (SGB) procedure. By targeting the brain's fight-or-flight response, the company provides a specialized medical intervention for patients suffering from trauma-related symptoms. Under the clinical guidance of Dr. Eugene Lipov, the organization has transitioned from a niche medical practice to a scalable enterprise model. Its market position is defined by its proprietary application of SGB, which offers a distinct alternative to traditional psychiatric medication, positioning Stella as a high-growth entity in the burgeoning field of trauma-informed medical care.
How much funding has Stella raised?
Stella has raised a total of $7M across 1 funding round:
Private Equity
$7M
Private Equity (2023): $7M, investors not publicly disclosed
Key Investors in Stella
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Stella?
With the infusion of this latest capital, Stella is expected to accelerate its operational scaling and clinical outreach. The strategic roadmap likely involves expanding the availability of the SGB procedure to a broader patient demographic while investing in clinical validation studies to further solidify its market authority. As the company moves beyond its initial development phase, the focus will shift toward standardizing its treatment protocols and potentially integrating its neurological intervention model into larger healthcare networks. This growth trajectory suggests a long-term commitment to addressing the global mental health crisis through evidence-based, procedural medicine.
See full Stella company page
